BiotechTube

Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo

Phase 3Recruiting
1 views this week 0 watching⚡ Active🔬Featured in Small-Cap Pipeline Watch
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Candidemia

Conditions

Candidemia, Candidiasis, Invasive

Trial Timeline

Dec 11, 2024 → Jan 30, 2028

NCT ID
NCT05421858

About Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo

Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo is a phase 3 stage product being developed by Basilea Pharmaceutica for Candidemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05421858. Target conditions include Candidemia, Candidiasis, Invasive.

What happened to similar drugs?

4 of 7 similar drugs in Candidemia were approved

Approved (4) Terminated (2) Active (2)
✅micafungin + Micafungin + CaspofunginAstellas PharmaApproved
✅MicafunginAstellas PharmaApproved
✅AmBisomeGilead SciencesApproved
✅Anidulafungin + VoriconazolePfizerApproved
❌Anidulafungin/FluconazolePfizerPhase 3
🔄Anidulafungin + FluconazolePfizerPhase 3
🔄AnidulafunginPfizerPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05421858Phase 3Recruiting

Competing Products

9 competing products in Candidemia

See all competitors
ProductCompanyStageHype Score
micafungin + Micafungin + CaspofunginAstellas PharmaApproved
43
MicafunginAstellas PharmaApproved
35
AmBisomeGilead SciencesApproved
43
Anidulafungin/FluconazolePfizerPhase 3
32
Anidulafungin + VoriconazolePfizerApproved
43
Anidulafungin + FluconazolePfizerPhase 3
40
AnidulafunginPfizerPhase 3
40
APX001Basilea PharmaceuticaPhase 2
29
APX001Basilea PharmaceuticaPhase 2
29